Avita Medical Stock Surge

Avita Medical (NASDAQ:RCEL) experienced a post-market stock increase of over 6% on Monday following the approval by the US Food and Drug Administration (FDA) of the premarket approval supplement for Recell Go mini.

This product is a new addition to the company’s skin-repair line, specifically designed for treating smaller wounds up to 480 square centimeters. The rollout of Recell Go mini will begin in trauma and burn centers that handle such wounds.

Jim Corbett, CEO of Avita Medical, stated that this FDA approval enhances their ability to offer targeted solutions for patients with full-thickness wounds. The rollout is expected to start in the first quarter of 2025.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.